LifeArc, as part of the CF AMR Syndicate, is providing £3m in collaborative funding to drug discovery innovators to accelerate the development of new treatments for people with cystic fibrosis.

The CF AMR Syndicate’s Collaborative Discovery Programme will support approximately five collaborative projects that aim to rapidly identify new antimicrobial therapies to treat chronic respiratory infections in people with CF.

The call is now closed to new applications.

The call was for researchers in academia and small and medium enterprises (SMEs) worldwide with projects expected to last up to two years, and total funding of up to £500,000 per project.

Successful applicants will benefit from a truly collaborative approach to drug development, with access to expert advice and practical support from managing partners Medicines Discovery Catapult (MDC), LifeArc and Cystic Fibrosis Trust.

The CF Syndicate in AMR is a cross-sector initiative that brings together leading experts in CF and AMR from industry, academia and the clinic with people with CF to accelerate the translation of CF antimicrobials to the clinic and bring new and effective treatment options to people with CF. The Syndicate was established in 2019 and is jointly managed by Medicines Discovery Catapult, Cystic Fibrosis Trust and LifeArc.

Expressions of interest closed on 9 May 2023. Shortlisted applicants were invited to a workshop in June 2023 prior to full application. Final funding decisions will be in October 2023, with an expectation of project initiation by the end of 2023. Key steps in the application process are summarised on the CF AMR Syndicate website.